SAR447971 Safety and Effectiveness Study
Part of Skin clinical trials.
This is an early-stage study testing a new drug called SAR447971 to see if it is safe and how the body handles it. There are two parts: one for healthy volunteers, and one for people with hidradenitis suppurativa (a chronic skin condition with painful bumps and drainage). The goal is to find out if this drug might help treat this skin condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old (healthy volunteers) or 18 and 65 years old (if you have hidradenitis suppurativa)
- Have no serious medical conditions or active infections requiring treatment in the past 4 weeks
- Not be taking immunosuppressant medications or have a weakened immune system
- If enrolling with hidradenitis suppurativa: have a diagnosis confirmed by a dermatologist at least 6 months ago
- If enrolling with hidradenitis suppurativa: have bumps in at least 2 different body areas with certain severity, and have not been treated with biologic drugs before
- Stop certain HS treatments (topical creams, antibiotics, other systemic drugs) for 2–4 weeks before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tests a new drug called LAD328 for hidradenitis suppurativa (HS), a chronic skin condition with painful lumps and abscesses. The trial is looking for adults with moderate-to-severe HS who haven't responded well to antibiotics to see if this new treatment can help reduce symptoms.
This study tests a new medicine called LAD191 for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. Researchers want to see if LAD191 safely reduces painful bumps and tunnels.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This trial tests a new drug called NAV-240 for people with hidradenitis suppurativa (HS) who have not had success with antibiotics. The goal is to see if the drug can reduce the number of painful lumps and improve symptoms.
Hear when a new Hidradenitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.